Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy (DiabPueblo)

2 settembre 2021 aggiornato da: Sansum Diabetes Research Institute

Diabetes Pueblo Program - The Application and Acceptability of Culturally Appropriate Education Programs for Current or Potential Insulin Therapy Users With Type 2 Diabetes in the Latino Community

Currently in the United States, the achieved level of glycemic control for adult Latinos with type 2 diabetes (T2D) is sub-optimal compared to the non-Latino Caucasian population. Among Latinos with T2D, there are unique barriers, such as socioeconomic and cultural factors, to starting and optimizing therapies, including insulin. Latinos have cultural beliefs and behaviors specific to this population that should be appropriately addressed in a diabetes self-management education and support program. Diabetes Pueblo is a diabetes education program that may be a solution to help address the barriers Latinos with T2D have to diabetes care and insulin use. The Diabetes Pueblo program consists of two targeted diabetes education curriculums for the local Latino community: (a) Diabetes Fundamentals and (b) Insulin Success, a culturally appropriate program course addressing barriers to initiating and optimizing insulin and T2D therapies. We will explore if Diabetes Pueblo Program improves knowledge of lifestyle advice for healthy eating and physical activity, increase the propensity to use insulin when clinically indicated, and improve success rates with insulin therapy by addressing common fears and negative perceptions of T2D therapies in this population.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Diabetes mellitus (DM) is a group of chronic disorders typified by raised blood glucose levels. An estimated 30 million people in the United States (US) (9.4% of the population) have diabetes. Type 1 diabetes (T1D) is defined by a rapid onset, often in childhood, and insulin dependence; while type 2 diabetes (T2D) is considered to have a slow onset and insulin insensitivity. Insulin is a required form of treatment for all T1D, and T2D patients who cannot achieve glycemic control through exercise and diet or other medications alone. Currently in the United States, the achieved level of glycemic control for adult Latinos with type 2 diabetes (T2D) is sub-optimal compared to the non-Latino Caucasian population. Among Latinos with T2D, there are unique barriers to starting and optimizing therapies, including insulin. Barriers include socioeconomic and cultural factors, as well as inadequate encouragement from health care providers. There are also challenges associated with access to timely and appropriate diabetes education. Some of these barriers may improve by using trained community health workers from the Latino community, as there is evidence that they are effective in supporting adherence and persistence with therapies (including insulin) and in encouraging lifestyle changes for T2D patients within their own communities.

The 2017 National Standards of Care for Diabetes Self-Management Education and Support (DSME/S) outline quality, evidenced based guidelines for DSME/S programs and guide those who will be providing these services. Benefits of DSME/S programs include improved clinical outcomes such as HbA1c and quality of life while reducing hospitalizations and health care costs. Hispanics are known to have a higher prevalence of diabetes, but use of DSME/S programs are vastly underutilized which means that many individuals in the Latino community with T2D are likely not receiving critical DSME/S services. It is crucial that DSME/S services be aligned with the needs of the target population in order to increase adherence and improve health outcomes. Latinos have cultural beliefs and behaviors specific to this population that should be appropriately addressed in a DSME/S program.

Diabetes Pueblo is a diabetes education program that may be a solution to help address the barriers Latinos with T2D have to diabetes care and insulin use. The Diabetes Pueblo program consists of two targeted diabetes education curriculums for the local Latino community: (a) Diabetes Fundamentals and (b) Insulin Success, a culturally appropriate program course addressing barriers to initiating and optimizing insulin and T2D therapies. Trained community health workers, also known as promotores, will deliver both programs. Ultimately, we will explore if Diabetes Pueblo Program improves knowledge of lifestyle advice for healthy eating and physical activity, increase the propensity to use insulin when clinically indicated, and improve success rates with insulin therapy by addressing common fears and negative perceptions of T2D therapies in this population.

This is a prospective pilot study. The Diabetes Pueblo program applied in this study is one program that consists of two newly created, targeted education curriculums for T2D Latino adults delivered over the course of 11 weeks by designated promotores, community health workers, to approximately 20 study participants at Sansum Diabetes Research Institute.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

25

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Santa Barbara, California, Stati Uniti, 93463
        • Sansum Diabetes Research Institute

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

19 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Individuals > 18 years of age
  2. Self-reported Latino heritage
  3. Fluent in Spanish
  4. Type 2 diabetes diagnosis
  5. Available to attend the educational series and all study visits
  6. Willingness to have height, weight, waist circumference, and HbA1c measured before and after the educational course
  7. Individuals with poor glycemic control, as defined by the following:

    • HbA1c ≥ 8% at or prior to enrollment assessment (most recent lab within 3 months or provided at Sansum Diabetes Research Institute (SDRI) screening visit),

    OR

    • HbA1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):

      • Fasting plasma glucose ≥ 130 mg/dL
      • 2-hour post-prandial or random blood glucose ≥ 180 mg/dL
      • ≥1 hypoglycemic event (blood glucose < 70 mg/dL)

    OR

    • Individuals new to insulin or being considered for insulin therapy by their healthcare provider
  8. Willing and able to provide consent to take part in the study
  9. Based on the research staff's judgment, participant must have a good understanding, ability, and willingness to adhere to the protocol

Exclusion Criteria:

  1. Has a cognitive impairment, hearing difficulty, visual impairment, acute psychopathology, medical condition, or insufficient knowledge of the education program language that, in the opinion of the screener, would interfere with the ability to provide consent and participate/complete the program
  2. Participation in other studies involving medications or device within 3 months prior to Visit 1
  3. Known or suspected abuse of alcohol, narcotics, or illicit drugs
  4. Current use of insulin pump
  5. For females: Pregnancy or positive pregnancy test
  6. Pharmaceutical employees or those employed in a position where they have a direct role in treating participants with diabetes.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Latino adults with type 2 diabetes

Participants of the Diabetes Pueblo Education Program will include adults with T2D from the Santa Barbara Latino community whose diabetes is poorly controlled, defined as -

  1. hemoglobin A1c > 8% at or prior to enrollment, or
  2. hemoglobin A1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):

    • Fasting plasma glucose > 130 mg/dL
    • 2-hour post-prandial or random blood glucose > 180 mg/dL
    • > 1 hypoglycemic event (blood glucose < 70 mg/dL) , or
  3. adults with T2D from the community who are new to insulin or being considered for insulin therapy by their healthcare provider.
These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes.
Lasso di tempo: 11 weeks
The Diabetes Pueblo program consists of two newly created, targeted education curriculums, Diabetes Fundamentals and Insulin Success, for Latino adults with type 2 diabetes. It will be delivered over the course of 11 weeks by designated promotores, community health workers, to approximately 20 study participants at Sansum Diabetes Research Institute.
11 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Diabetes self management evaluated by questionnaire
Lasso di tempo: Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class
The Diabetes Self-Management Questionnaire consists of 16 questions to evaluate diabetes self-care including glucose management, dietary control, physical activity, and health-care use. Questions are rated on a 4 point scale - 0 Does not apply to me, 1 Applies to me to some degree, 2 Applies to me to a considerable degree, 3 Applies to me very much. This yields an overall rating of self-care with higher scores indicating more effective diabetes self-care.
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class
Insulin treatment evaluated by questionnaire
Lasso di tempo: Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
The Insulin Treatment Appraisal Scale is a validated 20-item questionnaire that will be used in insulin naïve and insulin-treated patients with type 2 diabetes to assess positive and negative perceptions regarding insulin treatment. Items are rated on a 5-point scale ("strongly disagree" to "strongly agree") and the mean of individual item scores is calculated to obtain a total score, with lower scores indicating less negative perceptions regarding insulin treatment.
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Participant evaluation of Diabetes Pueblo evaluated by questionnaire
Lasso di tempo: Class 4, week 4; Class 8, week 8; Class 10, week 10
The first questionnaire includes curriculum content questions which are specific to courses 1-4, 5-8, and 9-10.
Class 4, week 4; Class 8, week 8; Class 10, week 10
Participant evaluation of Diabetes Pueblo evaluated by questionnaire
Lasso di tempo: Class 11, week 11
The second questionnaire assesses overall program feedback on the entire program.
Class 11, week 11

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Fingerstick for evaluation of HbA1c related to diabetes
Lasso di tempo: Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
HbA1c % will measured in a capillary fingerstick blood sample
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Height measured by Physical exam
Lasso di tempo: Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Height measured in centimeters or inches by physical exam
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Weight measured by Physical exam
Lasso di tempo: Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Weight measured in kilograms or pounds by physical exam
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Waist circumference measured by Physical exam
Lasso di tempo: Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Waist circumference measured in centimeters or inches by physical exam
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Socio-demographics assessed by questionnaire
Lasso di tempo: Visit 1, week 0 Screening
Socio-demographics measured by questionnaire - including age, gender, self-identified race/ethnicity, contact information, education, occupation, preferred language, insurance status, influenza & pneumonia immunization status, alcohol & tobacco use, birth place, physical activity, food security, and mobile phone use.
Visit 1, week 0 Screening
Foot examination evaluated by Questions
Lasso di tempo: Visit 1, week 0 Screening
Foot examination with 'yes or no' and frequency questions
Visit 1, week 0 Screening
Neuropathy Questions
Lasso di tempo: Visit 1, week 0 Screening
Questions about neuropathy
Visit 1, week 0 Screening
Retinopathy Questions
Lasso di tempo: Visit 1, week 0 Screening
Questions about retinopathy and eye exams
Visit 1, week 0 Screening
Nephropathy Questions
Lasso di tempo: Visit 1, week 0 Screening
Questions about nephropathy
Visit 1, week 0 Screening
Medical history and medication status and history assessed by questionnaire
Lasso di tempo: Visit 1, week 0 Screening
Medical history, including date of diabetes diagnosis, type of diabetes, diabetes education, diabetes self-care, depression and stress, falls, physician visits, hospital and emergency room visits, and current medications verified by visual inspection and medication history assessed by interview questionnaire
Visit 1, week 0 Screening
Menopausal status, pregnancy status, and gestational diabetes history for women determined by questionnaire
Lasso di tempo: Visit 1, week 0 Screening
Menopausal status, pregnancy status (number of live births, number of stillbirths, birthweights of live births, and any diagnosis of type 1 diabetes), and gestational diabetes history for female participants will be determined by questionnaire
Visit 1, week 0 Screening

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Jamie Creason, RD, Sansum Diabetes Research Institute

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 maggio 2019

Completamento primario (Effettivo)

25 febbraio 2020

Completamento dello studio (Effettivo)

25 febbraio 2020

Date di iscrizione allo studio

Primo inviato

9 luglio 2019

Primo inviato che soddisfa i criteri di controllo qualità

9 luglio 2019

Primo Inserito (Effettivo)

11 luglio 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 settembre 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 settembre 2021

Ultimo verificato

1 settembre 2021

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Diabetes Pueblo

Sottoscrivi